Carter Gould

Carter Gould Analyst Performance

Biopharma Equity Research at Cantor Fitzgerald

Carter Gould is a stock analyst at Cantor Fitzgerald focused in the healthcare sector, covering 18 publicly traded companies. Over the past year, Carter Gould has issued 51 stock ratings, including buy and hold recommendations. While full access to Carter Gould's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Carter Gould's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
115 Last 9 Years
Buy Recommendations
58.25% 60 Buy Ratings
Companies Covered
18 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy1.0%0 ratings
Buy57.3%59 ratings
Hold37.9%39 ratings
Sell3.9%3 ratings

Out of 103 total stock ratings issued by Carter Gould at Cantor Fitzgerald, the majority (57.3%) have been Buy recommendations, followed by 37.9% Hold, 3.9% Sell, and 1.0% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
12 companies
NYSE
33.3% of companies on NYSE
6 companies

Carter Gould, an analyst at Cantor Fitzgerald, currently covers 18 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
17 companies
94.4%
Technology
1 company
5.6%

Carter Gould of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector, with additional focus on Technology companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
12 companies
66.7%
PHARMACEUTICALS
5 companies
27.8%
SOFTWARE
1 company
5.6%

Carter Gould's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Amgen Inc. stock logo
AMGN
Amgen
11/4/2026Boost Price Target$461.26$465.00Neutral
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
11/3/2026Boost Price Target$553.15$619.00Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11/2/2026Boost Price Target$927.89$980.00Overweight
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
11/2/2026Boost Price Target$149.75$155.00Neutral
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
11/2/2026Boost Price Target$1,415.64$1,600.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
11/2/2026Boost Price Target$294.80$325.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
10/30/2026Boost Price Target$165.61$175.00Overweight
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
10/12/2026Reiterated Rating$71.38$120.00Overweight
Pfizer Inc. stock logo
PFE
Pfizer
10/8/2026Boost Price Target$27.96$28.00Neutral
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
10/8/2026Boost Price Target$142.66$145.00Neutral
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
10/8/2026Boost Price Target$1,186.95$1,440.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
10/8/2026Reiterated Rating$146.85$155.00Overweight
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
10/8/2026Lower Price Target$59.69$53.00Neutral
AbbVie Inc. stock logo
ABBV
AbbVie
10/8/2026Boost Price Target$271.37$290.00Overweight
Amgen Inc. stock logo
AMGN
Amgen
10/5/2026Boost Price Target$403.04$440.00Neutral
AbbVie Inc. stock logo
ABBV
AbbVie
9/16/2026Reiterated Rating$261.89$240.00Overweight
Amgen Inc. stock logo
AMGN
Amgen
9/8/2026Reiterated Rating$437.23$400.00Neutral
Amgen Inc. stock logo
AMGN
Amgen
8/18/2026Boost Price Target$419.38$400.00Neutral
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
8/6/2026Boost Price Target$1,170.30$1,410.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
8/5/2026Reiterated Rating$135.25$155.00Overweight
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
8/4/2026Boost Price Target$470.72$595.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
8/3/2026Boost Price Target$251.33$285.00Overweight
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
7/31/2026Reiterated Rating$63.97$59.00Neutral
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7/31/2026Boost Price Target$737.26$795.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
7/29/2026Reiterated Rating$132.94Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7/21/2026Lower Price Target$746.54$750.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
7/6/2026Boost Price Target$1,208.37$1,350.00Overweight
Pfizer Inc. stock logo
PFE
Pfizer
7/6/2026Reiterated Rating$24.29$27.00Neutral
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
7/6/2026Reiterated Rating$129.34$120.00Neutral
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
7/6/2026Reiterated Rating$131.27$155.00Overweight
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
7/6/2026Reiterated Rating$58.05$54.00Neutral
Amgen Inc. stock logo
AMGN
Amgen
7/6/2026Reiterated Rating$374.15$350.00Neutral
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7/6/2026Lower Price Target$654.27$750.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
7/6/2026Boost Price Target$260.88$265.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
6/23/2026Reiterated Rating$230.10Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
6/22/2026Reiterated Rating$1,098.78Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
6/16/2026Reiterated Rating$125.64$155.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
5/1/2026Boost Price Target$970.57$1,230.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
4/30/2026Reiterated Rating$213.96$240.00Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/23/2026Reiterated Rating$761.68$800.00Overweight
Your free book is about to disappear (Ad)

Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel

Download the Safe Trade Options Formula book for free before access closes
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4/8/2026Boost Price Target$57.68$54.00Neutral
Amgen Inc. stock logo
AMGN
Amgen
4/8/2026Reiterated Rating$340.00$350.00Neutral
AbbVie Inc. stock logo
ABBV
AbbVie
4/8/2026Lower Price Target$206.21$240.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/11/2026Boost Price Target$147.23$155.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/5/2026Boost Price Target$1,037.98$1,205.00Overweight
Pfizer Inc. stock logo
PFE
Pfizer
2/4/2026Reiterated Rating$26.73$27.00Neutral
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2/4/2026Boost Price Target$119.84$120.00Neutral
Amgen Inc. stock logo
AMGN
Amgen
2/4/2026Boost Price Target$364.01$350.00Neutral
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2/2/2026Boost Price Target$758.49$800.00Overweight
Pfizer Inc. stock logo
PFE
Pfizer
1/27/2026Boost Price Target$25.87$27.00Neutral
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/1/2025Reiterated Rating$1,069.22Overweight
Amgen Inc. stock logo
AMGN
Amgen
11/6/2025Boost Price Target$314.03$315.00Neutral
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10/31/2025Boost Price Target$98.17$112.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
10/31/2025Boost Price Target$845.87$985.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
10/31/2025Reiterated Rating$120.76$135.00Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
10/29/2025Boost Price Target$647.51$740.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
10/9/2025Set Price Target$845.55$925.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
10/9/2025Set Price Target$231.26$250.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
9/15/2025Boost Price Target$218.40$245.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
8/13/2025Lower Price Target$659.89$825.00Overweight
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
8/5/2025Lower Price Target$472.27$485.00Overweight
Amgen Inc. stock logo
AMGN
Amgen
6/24/2025Reiterated Rating$272.44$305.00Neutral
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5/20/2025Downgrade$77.92Cautious
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
5/13/2025Upgrade$30.00Strong-Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
5/6/2025Reiterated Rating$500.19$535.00Overweight
Salesforce Inc. stock logo
CRM
Salesforce
4/23/2025Initiated Coverage$255.39$210.00Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/22/2025Initiated Coverage$561.49$695.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4/22/2025Initiated Coverage$104.33$125.00Overweight
Amgen Inc. stock logo
AMGN
Amgen
4/22/2025Initiated Coverage$273.68$305.00Neutral
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4/22/2025Initiated Coverage$818.18$975.00Overweight
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4/22/2025Reiterated Rating$477.52$535.00Overweight
Pfizer Inc. stock logo
PFE
Pfizer
4/22/2025Initiated Coverage$22.07$24.00Neutral
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
4/22/2025Initiated Coverage$30.39Overweight
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4/22/2025Initiated Coverage$77.91$85.00Neutral
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4/22/2025Reiterated Rating$48.95$55.00Neutral
AbbVie Inc. stock logo
ABBV
AbbVie
4/22/2025Initiated Coverage$170.01$210.00Overweight